nach oben

International Journal of Clinical Oncology

Erschienen in:

27.09.2017 | Original Article

MMC/UFT/LV in refractory colorectal cancer: phase II study and analysis of predictive variables of progression

verfasst von: Chiara Baratelli, Marco Tampellini, Massimo Di Maio, Azzurra Ottone, Maria Pia Brizzi, Laura Forti, Irene Alabiso, Cristina Sonetto, Oscar Alabiso, Giorgio Vittorio Scagliotti

Erschienen in: International Journal of Clinical Oncology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

The treatment of refractory metastatic colorectal cancer (rmCRC) and the lack of predictive variables are matters of debate.

Patients and methods

We conducted a multicentre phase II trial assessing the disease control rate (DCR) of the combination of tegafur/uracil and mitomycin C in rmCRC. The number of previous lines of chemotherapy, carcinoembryonic antigen (CEA) levels, progression-free survival of the last chemotherapy regimen (PPFS), and the neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio at the time of study entry were evaluated as indicators of early progression.

Results

We enrolled 42 patients. The combination was well tolerated with a DCR of 26.2% and median overall survival of 6.9 months. Low CEA levels, PPFS >6 months and low NLR were significantly associated with better prognosis.

Conclusion

The study failed its primary endpoint. However, some putative indicators of early progressive patients have been described.

Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108CrossRefPubMed

Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22(1):23–30CrossRefPubMed

Hoff PM, Pazdur R, Benner SE, Canetta R (1998) UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Anticancer 9(6):479–490

Douillard JY, Hoff PM, Skillings JR et al (2002) Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. Clin Oncol 20(17):3605–3616CrossRef

Carmichael J, Popiela T, Radstone D et al (2002) Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20(17):3617–3627CrossRefPubMed

Paz MM, Zhang X, Lu J, Holmgren A (2012) A new mechanism of action for the anticancer drug mitomycin C: mechanism-based inhibition of thioredoxin reductase. Chem Res Toxicol 25(7):1502–1511CrossRefPubMed

Verweij J, Pinedo HM (1990) Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs 1(1):5–13CrossRefPubMed

Ferrarotto R, Machado K, Mak MP et al (2012) A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. Eur J Cancer 48(6):820–826CrossRefPubMed

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247CrossRefPubMed

10.

http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed Aug 2006

11.

Galizia G, Lieto E, Zamboli A et al (2015) Neutrophil to lymphocyte ratio is a strong predictor of tumor recurrence in early colon cancers: a propensity score-matched analysis. Surgery 158(1):112–120CrossRefPubMed

12.

Absenger G, Szkandera J, Pichler M et al (2013) A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer 109(2):395–400CrossRefPubMedPubMedCentral

13.

Neofytou K, Smyth EC, Giakoustidis A et al (2014) Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor. Med Oncol 31(10):239CrossRefPubMed

14.

Kodaira S (1997) Postoperative adjuvant chemotherapy with mitomycin C and UFT for rectal cancer. Oncology (Williston Park) 11(9 Suppl 10):40–43

15.

Nakagoe T, Ishikawa H, Sawai T et al (2000) Multicenter randomized prospective study of adjuvant chemotherapy with UFT and mitomycin C in advanced colorectal cancer. Anticancer Res 20(2B):1069–1075PubMed

16.

Gyldenkerne N, Glimelius B, Frödin JE et al (2004) A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer. Acta Oncol 43(3):276–279CrossRefPubMed

17.

Vormittag L, Kornek GV, Gruhsmann B et al (2007) UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer − a retrospective analysis. Anticancer Drugs 18(6):709–712CrossRefPubMed

18.

Alkis N, Demirci U, Benekli M et al (2011) Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure. J BUON 16(1):80–83PubMed

19.

Francois E, Smith D, Dahan L et al (2012) Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study. J Chemother 24(4):207–211CrossRefPubMed

20.

Michalaki V, Gennatas S, Gennatas C (2010) Mitomycin C and UFT/leucovorin as salvage treatment in patients with advanced colorectal cancer. J BUON 15(2):270–273PubMed

21.

Grothey A, Van Cutsem E, Sobrero A et al (2013) CORRECT Study Group: regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):303–312CrossRefPubMed

22.

Mayer RJ, Van Cutsem E, Falcone A et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372(20):1909–1919CrossRefPubMed

23.

Tampellini M, Ottone A, Alabiso I et al (2015) The prognostic role of baseline CEA and CA 19-9 values and their time-dependent variations in advanced colorectal cancer patients submitted to first-line therapy. Tumour Biol 36(3):1519–1527CrossRefPubMed

24.

Li MX, Liu XM, Zhang XF et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer 134(10):2403–2413CrossRefPubMed

25.

Del Prete M, Giampieri R, Loupakis F et al (2015) Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management. Oncotarget 6(32):33982–33992PubMedPubMedCentral

26.

Petrelli F, Coinu A, Cabiddu M et al (2015) Prognostic factors for survival with bevacizumab-based therapy in colorectal cancer patients: a systematic review and pooled analysis of 11,585 patients. Med Oncol 32(2):456CrossRefPubMed

27.

Giessen C, Laubender RP, Ankerst DP et al (2015) Surrogate endpoints in second-line treatment for mCRC: a systematic literature-based analysis from 23 randomised trials. Acta Oncol 54:187–193CrossRefPubMed

Titel: MMC/UFT/LV in refractory colorectal cancer: phase II study and analysis of predictive variables of progression
verfasst von: Chiara Baratelli
Marco Tampellini
Massimo Di Maio
Azzurra Ottone
Maria Pia Brizzi
Laura Forti
Irene Alabiso
Cristina Sonetto
Oscar Alabiso
Giorgio Vittorio Scagliotti
Publikationsdatum: 27.09.2017
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 2/2018
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-017-1195-x

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

MMC/UFT/LV in refractory colorectal cancer: phase II study and analysis of predictive variables of progression

Abstract

Background

Patients and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Patients and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Repeat cytoreduction and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal carcinomatosis of appendiceal origin

Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment

Esophageal squamous cell neoplasia is an independent negative prognostic factor for head and neck cancer patients

Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer

Associations between clinical data and computed tomography features in patients with epidermal growth factor receptor mutations in lung adenocarcinoma

Impact of a robotic surgical system on treatment choice for men with clinically organ-confined prostate cancer

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie